TY - JOUR
T1 - Emerging strategies for beta cell transplantation to treat diabetes
AU - Paez-Mayorga, Jesus
AU - Lukin, Izeia
AU - Emerich, Dwaine
AU - de Vos, Paul
AU - Orive, Gorka
AU - Grattoni, Alessandro
N1 - Funding Information:
The authors are grateful to Dr. Marco Farina for insightful discussion and information. The authors thank the graphic designer Virginia Facciotto ([email protected]) for the preparation of schematics and illustrations. Funding support is obtained from JDRF 2-SRA-2021-1078-S-B (A.G.), Vivian L. Smith Foundation (A.G.), and JDRF 2-SRA-2018-523-S-B (P.d.V.). G.O. thanks the Spanish Ministry of Economy, Industry, and Competitiveness (PID2019-106094RB-I00/AEI/10.13039/501100011033) and technical assistance from the ICTS NANBIOSIS (Drug Formulation Unit, U10) at the University of the Basque Country. We also appreciate the support from the Basque Country Government (Grupos Consolidados, No ref: IT907-16). I.L. thanks the Basque Government for the PhD grant (PRE_2020_2_0094). A.G. and J.P-M. are inventors of intellectual properties licensed by NanoGland, LLC.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2022/3
Y1 - 2022/3
N2 - Beta cell replacement has emerged as an attractive therapeutic alternative to traditional exogenous insulin administration for management of type 1 diabetes (T1D). Beta cells deliver insulin dynamically based on individual glycometabolic requirements, providing glycemic control while significantly reducing patient burden. Although transplantation into the portal circulation is clinically available, poor engraftment, low cell survival, and immune rejection have sparked investigation of alternative strategies for beta cell transplantation. In this review, we focus on current micro- and macroencapsulation technologies for beta cell transplantation and evaluate their advantages and challenges. Specifically, we comment on recent methods to ameliorate graft hypoxia including enhanced vascularization, reduction of pericapsular fibrotic overgrowth (PFO), and oxygen supplementation. We also discuss emerging beta cell-sourcing strategies to overcome donor shortage and provide insight into potential approaches to address outstanding challenges in the field.
AB - Beta cell replacement has emerged as an attractive therapeutic alternative to traditional exogenous insulin administration for management of type 1 diabetes (T1D). Beta cells deliver insulin dynamically based on individual glycometabolic requirements, providing glycemic control while significantly reducing patient burden. Although transplantation into the portal circulation is clinically available, poor engraftment, low cell survival, and immune rejection have sparked investigation of alternative strategies for beta cell transplantation. In this review, we focus on current micro- and macroencapsulation technologies for beta cell transplantation and evaluate their advantages and challenges. Specifically, we comment on recent methods to ameliorate graft hypoxia including enhanced vascularization, reduction of pericapsular fibrotic overgrowth (PFO), and oxygen supplementation. We also discuss emerging beta cell-sourcing strategies to overcome donor shortage and provide insight into potential approaches to address outstanding challenges in the field.
KW - Microencapsulation
KW - immune rejection
KW - immunoisolation
KW - macroencapsulation
KW - pancreatic islets
KW - vascularization
KW - Diabetes Mellitus, Type 1/surgery
KW - Humans
KW - Insulin/metabolism
KW - Islets of Langerhans Transplantation/methods
KW - Islets of Langerhans/metabolism
UR - http://www.scopus.com/inward/record.url?scp=85120685935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120685935&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2021.11.007
DO - 10.1016/j.tips.2021.11.007
M3 - Review article
C2 - 34887129
AN - SCOPUS:85120685935
SN - 0165-6147
VL - 43
SP - 221
EP - 233
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
IS - 3
ER -